Skip to content

Total at other companies

Merck & Co. logo
Merck & Co.MRK
BridgeBio Pharma logo
BridgeBio PharmaBBIO
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
Amgen logo
AmgenAMGN
Biogen logo
BiogenBIIB

Other financials

Income statement

See full
Revenue-
Operating income-$45.6M+14.8%
Net income-$69.0M-54.1%
EPS (diluted)-$0.74-23.3%

Balance sheet

See full
Cash & equivalents$97.2M+100%
Total debt$4.3M-9.6%
Total equity$670.8M+39.0%
Total assets$764.0M+34.1%

Cash flow

See full
Operating cash flow-$57.4M-40.0%
CapEx-
Free cash flow-$39.4M-26.8%

Valuation

See full
Market cap$7.67B+307%

Profitability

See full
Operating margin-39,428.9%-49,795pp
Net margin-52,939.7%-61,871pp
FCF margin-3,442.8%-3,807pp

Returns & leverage

See full
Return on equity-31.1%-10.7pp
Debt / equity0.1×+0.1×
Current ratio+0.9×

Where this comes from

Reported directly by Spyre Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis.

The official record: Spyre Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Spyre Therapeutics, Inc.'s total.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Spyre Therapeutics, Inc.'s total?
Spyre Therapeutics, Inc. (SYRE) reported total of $645.05M in Q1 2026.
How has Spyre Therapeutics, Inc.'s total changed year-over-year?
Spyre Therapeutics, Inc.'s total increased by 25.1% year-over-year, from $515.68M to $645.05M.
What is the long-term trend for Spyre Therapeutics, Inc.'s total?
Over 3 years (2022 to 2025), Spyre Therapeutics, Inc.'s total has grown at a 217.8% compound annual growth rate (CAGR), from $20.88M to $669.94M.